Mechanism of Action
BB1 Receptor Signaling
NMB binds BB1 (NMBR) with higher affinity than BB2 (gastrin-releasing peptide receptor, GRPR). BB1 couples to Gq/11 and Gi proteins, activating phospholipase C and raising intracellular calcium, while also activating MAP kinase and PI3K signaling. These pathways mediate smooth muscle contraction, exocrine secretion stimulation, and CNS neuronal modulation. BB1 also transactivates epidermal growth factor receptor (EGFR), contributing to proliferative effects in cancer.
CNS and Behavioral Effects
NMB in the amygdala and parabrachial nucleus modulates fear conditioning and itch sensation. BB1 receptor knockout mice show deficits in itch-induced scratch behavior and altered fear extinction. NMB neurons in the spinal cord and parabrachial nucleus transmit histamine-independent itch signals. The role of NMB in itch processing has therapeutic implications for chronic pruritus conditions including atopic dermatitis.
Research Summary
Feeding and Satiety
Preclinical StrongICV NMB reduces food intake in rodents in a BB1 receptor-dependent manner. BB1 knockout mice show increased obesity on high-fat diet. NMB neurons in the dorsomedial hypothalamus project to feeding-relevant circuits. Combined BB1/BB2 antagonism reduces food intake more than single blockade, suggesting complementary roles for NMB and GRP in satiety circuits.
Itch (Pruritus)
Active ResearchNMB-positive neurons in the dorsal spinal cord and parabrachial nucleus form a dedicated itch circuit. BB1 antagonists reduce chronic itch in atopic dermatitis models. An anti-NMB antibody (CDP7657/NMB mAb approaches) and small-molecule BB1 antagonists are in early development for atopic dermatitis and other chronic pruritic conditions. NMB represents a non-histaminergic, non-opioid itch transmission pathway.
Cancer Targeting
Active ResearchBB1/NMBR is overexpressed in lung cancer (SCLC), prostate cancer, colorectal cancer, and others. Radiolabeled bombesin analogs targeting BB1/BB2 are used for PET imaging and targeted radiotherapy (theranostics) of BB receptor-expressing tumors. NMB-based peptide conjugates for targeted drug delivery represent a growing oncological application.
Calculate your Neuromedin B dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Satiety/feeding research | 1-10 nmol ICV or 5-25 nmol/kg IP in rodent studies | Per research session | Intracerebroventricular or intraperitoneal |
| Itch circuit research | 0.1-1 nmol intrathecal in rodents | Per session | Intrathecal |
Research tool only. No approved human therapeutic. BB1 receptor-targeting theranostic peptides are the most advanced clinical application.
Interactions
Safety Profile
No human safety data for NMB itself. Research doses in animals produce smooth muscle contraction (GI cramping), increased pancreatic secretion, and CNS behavioral changes. BB1/BB2 antagonists in clinical development have shown acceptable tolerability in Phase 1. Oncological radiolabeled bombesin analogs have established safety profiles in nuclear medicine. No significant systemic toxicity expected at pharmacological doses based on preclinical data.
References
- [1]Minamino N, et al. Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun. 1983;114(2):541-548.
- [2]Sukhtankar DD, Ko MC. Physiological function of gastrin-releasing peptide and neuromedin B receptors in regulating itch scratching behavior in the spinal cord of mice. PLoS One. 2013;8(6):e67422.